RxDoctor Payments Data

Sanjuana Gonzalez

Family · Tupelo, MSNPI 1609576529

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 82 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$424
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$372
  • Novo Nordisk$189
  • Phathom Pharmaceuticals, Inc.$183
  • Boehringer Ingelheim$175
  • Axsome Therapeutics, Inc.$129
  • plus $384 from 8 others

What the payments were for

  • Food & beverage$1,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,948
Medicare patients
45
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$46,796
FarxigaDapagliflozin Propanediol29$39,552
JardianceEmpagliflozin20$31,697
Tresiba Flextouch U-100Insulin Degludec11$8,547
Gabapentin41$599
Fluticasone Propionate28$426
Famotidine15$311
Rosuvastatin Calcium42$253
Tizanidine Hcl19$250
Atorvastatin Calcium44$222
Levothyroxine Sodium39$211
Pantoprazole Sodium25$185
Montelukast Sodium20$170
Metformin Hcl ErMetformin Hcl11$148
Omeprazole11$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$48$39,55229 claims
Boehringer IngelheimJardiance$175$31,69720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →